Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer

Core Viewpoint - Aquestive Therapeutics has appointed Dr. Matthew Greenhawt as Chief Medical Officer to support the resubmission of the Anaphylm™ New Drug Application (NDA) and advance its clinical pipeline [1][2][3] Company Leadership and Expertise - Dr. Greenhawt is an internationally recognized expert in allergy and immunology, bringing extensive clinical, research, and advocacy experience to the company at a critical time [2][4] - The appointment is seen as a strong addition to the leadership team, with Dr. Greenhawt's expertise expected to be invaluable for FDA approval efforts [3] Product Development - Anaphylm™ (dibutepinephrine) is a sublingual film designed for the emergency treatment of anaphylaxis, which is expected to be the first oral medication for severe allergic reactions if approved by the FDA [7] - The product is designed to be user-friendly, dissolving on contact without the need for water or swallowing, and is compact enough to be carried easily [7] Company Background - Aquestive Therapeutics focuses on advancing medicines through innovative science and delivery technologies, operating as both a product developer and a Contract Development and Manufacturing Organization (CDMO) [8] - The company has a portfolio that includes four commercialized products and is advancing multiple product candidates, including Anaphylm and AQST-108 for various indications [8]